Literature DB >> 26757043

Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study.

Assaf Shelef1, Yoram Barak1, Uri Berger2, Diana Paleacu1, Shelly Tadger1, Igor Plopsky1, Yehuda Baruch1.   

Abstract

BACKGROUND: Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD).
OBJECTIVE: To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD).
METHODS: Eleven AD patients were recruited to an open label, 4 weeks, prospective trial.
RESULTS: Ten patients completed the trial. Significant reduction in CGI severity score (6.5 to 5.7; p <  0.01) and NPI score were recorded (44.4 to 12.8; p <  0.01). NPI domains of significant decrease were: Delusions, agitation/aggression, irritability, apathy, sleep and caregiver distress.
CONCLUSION: Adding MCO to AD patients' pharmacotherapy is safe and a promising treatment option.

Entities:  

Keywords:  Alzheimer’s disease; behavioral and psychological symptoms of dementia; cannabis; tetrahydrocannabinol

Mesh:

Substances:

Year:  2016        PMID: 26757043     DOI: 10.3233/JAD-150915

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  28 in total

Review 1.  The Use of Cannabinoids in Treating Dementia.

Authors:  Megan Weier; Wayne Hall
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08       Impact factor: 5.081

Review 2.  Cannabinoids for Agitation in Alzheimer's Disease.

Authors:  John D Outen; M Haroon Burhanullah; Ryan Vandrey; Halima Amjad; David G Harper; Regan E Patrick; Rose L May; Marc E Agronin; Brent P Forester; Paul B Rosenberg
Journal:  Am J Geriatr Psychiatry       Date:  2021-01-27       Impact factor: 4.105

Review 3.  Medical cannabis: aligning use to evidence-based medicine approach.

Authors:  Lihi Bar-Lev Schleider; Ran Abuhasira; Victor Novack
Journal:  Br J Clin Pharmacol       Date:  2018-08-28       Impact factor: 4.335

Review 4.  Targeting the endocannabinoid system: a predictive, preventive, and personalized medicine-directed approach to the management of brain pathologies.

Authors:  Vamsi Reddy; Dayton Grogan; Meenakshi Ahluwalia; Évila Lopes Salles; Pankaj Ahluwalia; Hesam Khodadadi; Katelyn Alverson; Andy Nguyen; Srikrishnan P Raju; Pankaj Gaur; Molly Braun; Fernando L Vale; Vincenzo Costigliola; Krishnan Dhandapani; Babak Baban; Kumar Vaibhav
Journal:  EPMA J       Date:  2020-04-15       Impact factor: 6.543

Review 5.  Targeting Inflammatory Pathways in Alzheimer's Disease: A Focus on Natural Products and Phytomedicines.

Authors:  Matthew J Sharman; Giuseppe Verdile; Shanmugam Kirubakaran; Cristina Parenti; Ahilya Singh; Georgina Watt; Tim Karl; Dennis Chang; Chun Guang Li; Gerald Münch
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

Review 6.  Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia.

Authors:  Mehnaz Ahmed; Marlene Malik; Johannes Teselink; Krista L Lanctôt; Nathan Herrmann
Journal:  Drugs Aging       Date:  2019-07       Impact factor: 3.923

Review 7.  Apathy in Dementia: Systematic Review of Recent Evidence on Pharmacological Treatments.

Authors:  Fleur Harrison; Liesbeth Aerts; Henry Brodaty
Journal:  Curr Psychiatry Rep       Date:  2016-11       Impact factor: 5.285

8.  Agitation in Alzheimer Disease as a Qualifying Condition for Medical Marijuana in the United States.

Authors:  Donovan T Maust; Erin E Bonar; Mark A Ilgen; Frederic C Blow; Helen C Kales
Journal:  Am J Geriatr Psychiatry       Date:  2016-04-11       Impact factor: 4.105

9.  Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis.

Authors:  Anees Bahji; Arthi Chinna Meyyappan; Emily R Hawken
Journal:  Can J Psychiatry       Date:  2019-12-13       Impact factor: 4.356

10.  Safety and Tolerability of Natural and Synthetic Cannabinoids in Older Adults: A Systematic Review and Meta-Analysis of Open-Label Trials and Observational Studies.

Authors:  Latha Velayudhan; Sagnik Bhattacharyya; Sara Pisani; Katie McGoohan
Journal:  Drugs Aging       Date:  2021-07-08       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.